BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9391397)

  • 1. Telemedicine project looks to improve ESRD care, lower costs. TRC/Georgetown University Medical Center begin two-year experiment.
    Neumann ME
    Nephrol News Issues; 1997 Oct; 11(10):67-9. PubMed ID: 9391397
    [No Abstract]   [Full Text] [Related]  

  • 2. Managed care is not the "cure-all" for improving quality and controlling costs in ESRD.
    Amerling R
    Nephrol News Issues; 1999 Apr; 13(4):46-7. PubMed ID: 10418448
    [No Abstract]   [Full Text] [Related]  

  • 3. ESRD demonstration aligns incentives.
    Neumann ME
    Nephrol News Issues; 2011 Feb; 25(2):8. PubMed ID: 21466017
    [No Abstract]   [Full Text] [Related]  

  • 4. Dialysis care in 1999: reality and challenges.
    Bosch JP; Bander S
    J Nephrol; 2000; 13 Suppl 3():S7-9. PubMed ID: 11132036
    [No Abstract]   [Full Text] [Related]  

  • 5. The direction of end-stage renal disease reimbursement in the United States.
    Lockridge RS
    Semin Dial; 2004; 17(2):125-30. PubMed ID: 15043614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs take the spotlight in steering clinical, economic direction for ESRD.
    Neumann ME
    Nephrol News Issues; 2004 Jun; 18(7):50-1. PubMed ID: 15232997
    [No Abstract]   [Full Text] [Related]  

  • 7. How telehomecare affects patients.
    Dansky KH; Bowles KH; Palmer L
    Caring; 1999 Aug; 18(8):10-4. PubMed ID: 10557966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A patient-directed fee-for-service system can work for ESRD.
    Amerling R
    Nephrol News Issues; 2002 Sep; 16(10):25-6. PubMed ID: 12271926
    [No Abstract]   [Full Text] [Related]  

  • 9. Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care.
    Manns B; Meltzer D; Taub K; Donaldson C
    Health Econ; 2003 Nov; 12(11):949-58. PubMed ID: 14601157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HMOs and ESRD: a gloomy scenario.
    Steinman TI
    Nephrol News Issues; 1998 May; 12(5 Suppl):30, 33. PubMed ID: 9652298
    [No Abstract]   [Full Text] [Related]  

  • 11. Current status of end-stage renal disease care in South Asia.
    Jha V
    Ethn Dis; 2009; 19(1 Suppl 1):S1-27-32. PubMed ID: 19484871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges and directions for Medicare ESRD payment policy.
    Ray NF; Ross M
    Semin Nephrol; 2000 Nov; 20(6):565-76. PubMed ID: 11111858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost functions for dialysis facilities and the quality of dialysis.
    Escarce JJ; Feldman HI
    Health Serv Res; 1999 Feb; 33(6):1563-6. PubMed ID: 10029497
    [No Abstract]   [Full Text] [Related]  

  • 14. [Cost-effectiveness analysis of treatment for end-stage renal disease].
    Asgeirsdóttir TL; Asmundsdóttir G; Heimisdóttir M; Jónsson E; Pálsson R
    Laeknabladid; 2009 Nov; 95(11):747-53. PubMed ID: 19996463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ESRD as a window into America's cost crisis in health care.
    Knauf F; Aronson PS
    J Am Soc Nephrol; 2009 Oct; 20(10):2093-7. PubMed ID: 19729435
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of information technology to improve quality of healthcare: Kosova's telemedicine project and international virtual e-hospital as an example.
    Latifi R; Muja S; Bekteshi F; Reinicke M
    Stud Health Technol Inform; 2004; 104():159-67. PubMed ID: 15747975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ESRD data system needs a fix. Lack of updates impacts beneficiaries, costs Medicare; USRDS looks elsewhere for accurate data.
    Nephrol News Issues; 2002 Apr; 16(5):8, 10. PubMed ID: 11962159
    [No Abstract]   [Full Text] [Related]  

  • 18. Evidence missing to support moving ESRD patients into HMOs.
    Charytan C
    Nephrol News Issues; 2000 Jul; 14(8):13-4. PubMed ID: 12101515
    [No Abstract]   [Full Text] [Related]  

  • 19. Methodological considerations for end-of-life research in patients with chronic kidney disease.
    Davidson SN; Murtagh FE; Higginson IJ
    J Nephrol; 2008; 21(3):268-82. PubMed ID: 18587713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of the cost of treatment for terminal chronic renal insufficiency. Thoughts on the value of this type of study and the role of the nephrologist].
    Pollini J; Soutif C; Barnouin F; Briat C; Meulders Q; Teissier M
    Nephrologie; 1998; 19(5):245-53. PubMed ID: 9793937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.